In this episode, David interviews Professor Celia Morgan, Ph.D., who holds the Chair of Psychopharmacology and co-leads the Transdisciplinary Psychedelics Group at The University of Exeter. This was recorded on the dawn of UK's Breaking Convention conference, where Morgan was speaking about the therapeutic potential of ketamine as well as the danger of people developing a dependence on it. She touches on that topic, but largely discusses her current Phase III Trial for ketamine-assisted therapy for the treatment of severe alcohol use disorder (also called the KARE model (Ketamine for reduction of Alcohol Relapse)), a collaboration with Awakn Life Sciences. She discusses her other research: studies on mindfulness intervention before and after ketamine, epigenetic changes after ayahuasca use, the antidepressant qualities of ayahuasca, and CBD for cannabis dependence. And she talks about the necessary balance for making treatments amazing but affordable; how connecting with nature during integration is key; how the drug is just a tool, yet we focus on it too much; and how we need studies on how different therapies work with different substances. www.psychedelicstoday.com